These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 29762866)

  • 1. Obesity as an immune-modifying factor in cancer immunotherapy.
    Canter RJ; Le CT; Beerthuijzen JMT; Murphy WJ
    J Leukoc Biol; 2018 Sep; 104(3):487-497. PubMed ID: 29762866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapies, their safety and toxicity.
    Alatrash G; Jakher H; Stafford PD; Mittendorf EA
    Expert Opin Drug Saf; 2013 Sep; 12(5):631-45. PubMed ID: 23668362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes.
    Turbitt WJ; Buchta Rosean C; Weber KS; Norian LA
    Immunol Rev; 2020 May; 295(1):203-219. PubMed ID: 32157710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmunity associated with immunotherapy of cancer.
    Amos SM; Duong CP; Westwood JA; Ritchie DS; Junghans RP; Darcy PK; Kershaw MH
    Blood; 2011 Jul; 118(3):499-509. PubMed ID: 21531979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of cancer immunotherapy toxicity.
    Kennedy LB; Salama AKS
    CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity induced T cell dysfunction and implications for cancer immunotherapy.
    Aguilar EG; Murphy WJ
    Curr Opin Immunol; 2018 Apr; 51():181-186. PubMed ID: 29655021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
    Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
    J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. When fat is favorable: the unexpected relationship between obesity and response to immunotherapy.
    Jin J; Stabile LP
    Immunotherapy; 2020 Oct; 12(14):1035-1039. PubMed ID: 32878516
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cancer immunotherapy by immuno-checkpoint blockade].
    Kawakami Y
    Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicities of Immunotherapy for the Practitioner.
    Weber JS; Yang JC; Atkins MB; Disis ML
    J Clin Oncol; 2015 Jun; 33(18):2092-9. PubMed ID: 25918278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mechanisms of immunotherapy toxicities in the era of genome-wide association studies.
    Gusev A
    Immunol Rev; 2023 Sep; 318(1):138-156. PubMed ID: 37515388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy.
    Possick JD
    Clin Chest Med; 2017 Jun; 38(2):223-232. PubMed ID: 28477635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer immunotherapy and the management of side effects.
    Mahalingam P; Newsom-Davis T
    Clin Med (Lond); 2023 Jan; 23(1):56-60. PubMed ID: 36697001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Kidney Injury in Cancer Immunotherapy Recipients.
    Joseph A; Lafarge A; Azoulay E; Zafrani L
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
    Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
    Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Toxicities Associated with Cancer Immunotherapies.
    Wang DY; Okoye GD; Neilan TG; Johnson DB; Moslehi JJ
    Curr Cardiol Rep; 2017 Mar; 19(3):21. PubMed ID: 28220466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors.
    Ciccarese C; Alfieri S; Santoni M; Santini D; Brunelli M; Bergamini C; Licitra L; Montironi R; Tortora G; Massari F
    Expert Opin Drug Metab Toxicol; 2016; 12(1):57-75. PubMed ID: 26565919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.